BACKGROUND: A high level of circulating DNA (cirDNA) in cancer patients has been correlated with poor outcomes. Studies have demonstrated the critical contributions of the tumor-derived cirDNA. In this report, we investigated the roles of the non-tumor-derived cirDNA (nt-cirDNA) in determining the prognosis of non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: Plasma samples from 58 advanced NSCLC patients and 52 controls were collected. The nt-cirDNA levels were assessed with qPCR assay to detect the unmethylation status of an epithelial-specific marker, the SHP-1 promoter 2 (unmethylated SHP1P2). Clinicopathological correlations were analyzed. RESULTS: There was a significant increase in the total amount of cirDNA in NSCLC patients compared with controls: 4.3 ng ml(-1) [0.82-49.8] and 2.0 ng ml(-1) [0.03-26.9], respectively (p < 0.01). An increased amount of the unmethylated SHP1P2 in advanced NSCLC was also detected: 3.4 ng ml(-1) [1.2-24.8] versus 2.0 ng ml(-1) [0.03-26.9] in the controls (p = 0.026). Survival analyses revealed that high levels of total cirDNA and unmethylated SHP1P2 were significantly associated with decreased survival. However, the total cirDNA had a better prognostic correlation than the unmethylated SHP1P2. Multivariate analysis identified total cirDNA (p = 0.004) and systemic treatment (p = 0.002) as independent prognostic parameters. CONCLUSION: The level of total cirDNA in NSCLC is an important prognostic parameter that demonstrates the contributions from both tumor-derived sources and non-tumor-derived sources.
BACKGROUND: A high level of circulating DNA (cirDNA) in cancerpatients has been correlated with poor outcomes. Studies have demonstrated the critical contributions of the tumor-derived cirDNA. In this report, we investigated the roles of the non-tumor-derived cirDNA (nt-cirDNA) in determining the prognosis of non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: Plasma samples from 58 advanced NSCLCpatients and 52 controls were collected. The nt-cirDNA levels were assessed with qPCR assay to detect the unmethylation status of an epithelial-specific marker, the SHP-1 promoter 2 (unmethylated SHP1P2). Clinicopathological correlations were analyzed. RESULTS: There was a significant increase in the total amount of cirDNA in NSCLCpatients compared with controls: 4.3 ng ml(-1) [0.82-49.8] and 2.0 ng ml(-1) [0.03-26.9], respectively (p < 0.01). An increased amount of the unmethylated SHP1P2 in advanced NSCLC was also detected: 3.4 ng ml(-1) [1.2-24.8] versus 2.0 ng ml(-1) [0.03-26.9] in the controls (p = 0.026). Survival analyses revealed that high levels of total cirDNA and unmethylated SHP1P2 were significantly associated with decreased survival. However, the total cirDNA had a better prognostic correlation than the unmethylated SHP1P2. Multivariate analysis identified total cirDNA (p = 0.004) and systemic treatment (p = 0.002) as independent prognostic parameters. CONCLUSION: The level of total cirDNA in NSCLC is an important prognostic parameter that demonstrates the contributions from both tumor-derived sources and non-tumor-derived sources.
Authors: Oliver Gautschi; Colette Bigosch; Barbara Huegli; Monika Jermann; Arthur Marx; Eveline Chassé; Daniel Ratschiller; Walter Weder; Markus Joerger; Daniel C Betticher; Rolf A Stahel; Annemarie Ziegler Journal: J Clin Oncol Date: 2004-10-15 Impact factor: 44.544
Authors: Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos Journal: N Engl J Med Date: 2003-01-16 Impact factor: 91.245
Authors: Matthias Zitt; Hannes M Müller; Marina Rochel; Verena Schwendinger; Marion Zitt; Georg Goebel; Alexander Devries; Raimund Margreiter; Michael Oberwalder; Robert Zeillinger; Dietmar Ofner Journal: Dis Markers Date: 2008 Impact factor: 3.434
Authors: A Szpechcinski; J Chorostowska-Wynimko; R Struniawski; W Kupis; P Rudzinski; R Langfort; E Puscinska; P Bielen; P Sliwinski; T Orlowski Journal: Br J Cancer Date: 2015-06-30 Impact factor: 7.640
Authors: Dolores C García-Olmo; María G Picazo; Inmaculada Toboso; Ana I Asensio; Damián García-Olmo Journal: Mol Cancer Date: 2013-02-04 Impact factor: 27.401
Authors: Myung Han Hyun; Jae Sook Sung; Eun Joo Kang; Yoon Ji Choi; Kyong Hwa Park; Sang Won Shin; Sung Yong Lee; Yeul Hong Kim Journal: Oncotarget Date: 2017-10-10